Journal of Virology & Antiviral ResearchISSN: 2324-8955

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Nanoparticle Vaccine for Avian Influenza Virus: A Challenge Study against Highly Pathogenic H5N2 Subtype

We used a platform of self-assembling protein nanoparticles (SAPNs) to develop a self-adjuvanted vaccine for avian influenza virus (AIV). A SAPNs named SA-MC-Penn was designed to display the ectodomain of influenza matrix protein 2 (M2e) as a tetramer and Helix C (Hel C) of hemagglutinin as a trimer. Flagellin domains
expressed within a peptide chain were co-assembled into the SAPN core serving as a built-in adjuvant. SA-MC-Penn was administered every two weeks for three times via the intramuscular (IM) or eye drop (ED) routes in chickens starting at four-weeks of age. Sera were collected from immunized chickens at twelve-weeks of age prior to challenge with a highly pathogenic (HP) H5N2 strain of AIV. ELISA results demonstrated that high titers of serum antibodies were induced in the IM immunized SAPNs. Upon challenge with HP AIV, 63 % and 30% of chickens the SAPNs IM and SAPN ED groups, respectively, survived. A reduction in challenge virus shedding from oropharyngeal swabbings of the SAPNs IM vaccinates was observed on days two and 14-post challenge. These results show the SAPNs vaccine prototype was partially protective against HPAIV.

Special Features

Full Text


Track Your Manuscript

Media Partners